"The therapeutic footprint of this drug class is expanding year on year," said Hala Zakaria, Innovation, Research and Operations Manager at Metabolic, formerly GluCare.Health
A recent 2022 Phase 2 randomized, double-blind, placebo-controlled trial funded by the NIH evaluated the effects of D-Ribose and Ubiquinol in patients with heart failure with preserved ejection fraction (HFpEF)
Finally, given the observational design of the study, the findings reflect associations rather than causal relationships
Feldman et al., 2022)
This energy enhancement happened because NAD+ helps your mitochondriatiny cellular powerhouses that make ATP, your body's energy currency [5]
More recent data suggesting that FGF21 plays a role in mediating these events needs further confirmation (72)